之法律意见书 致：成都市贝瑞和康基因技术股份有限公司 北京市金杜律师事务所（以下简称本所）接受成都市贝瑞和康基因技术股份 有限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证 券法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督 管理委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共 和国境内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行 政区、中国澳门特别行政区和中国台湾地区）现行有效的法律、行政法规、规章 和规范性文件和现行有效的公司章程有关规定，指派律师现场出席了公司于 2025 年 5 月 20 日召开的 2024 年年度股东大会（以下简称本次股东大会），并 就本次股东大会相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1. 经公司 2023 年年度股东大会审议通过的《成都市贝瑞和康基因技术股份 有限公司章程》（以下简称《公司章程》）； 北京市金杜律师事务所 关于成都市贝瑞和康基因技术股份有限公司 2024 年年度股东大会 2. 公司 2025 年 4 月 25 日刊登于《中国证券报 ...

Core Viewpoint - The forced liquidation of shares held by the controlling shareholder, Gao Yang, due to a default in a stock pledge repurchase agreement, raises concerns about the financial stability of Berry Genomics and its declining stock price [1][2][5] Group 1: Shareholder Actions and Impacts - Gao Yang, the founder and chairman of Berry Genomics, has had 3,535,214 shares (1% of total shares) ordered for forced liquidation due to a default on a stock pledge with Guosen Securities [1] - All shares held by Gao Yang (9.05% of total shares) are currently under judicial freeze, indicating significant financial distress [3] - The forced execution of shares is part of a broader trend where both Gao Yang and his associate, Hou Ying, have seen their shares subjected to judicial auction due to ongoing financial difficulties [4] Group 2: Financial Performance - Berry Genomics has experienced a continuous decline in revenue and has reported losses for four consecutive years, totaling approximately 9.85 billion yuan [5] - The company's revenue figures from 2021 to 2024 are approximately 14.22 billion yuan, 13.68 billion yuan, 11.51 billion yuan, and 10.78 billion yuan, respectively, with net profits turning negative starting in 2021 [5] - The decline in performance is attributed to market demand changes and increased competition, leading to significant asset impairment provisions [5] Group 3: Stock Performance - The stock price of Berry Genomics has plummeted from a peak of 98 yuan per share in July 2020 to below 10 yuan per share in 2023, reflecting a severe loss of investor confidence [2] - As of May 19, the stock closed at 13.40 yuan per share, down 5.57% [5]

Core Viewpoint - The announcement highlights that a significant shareholder of Berry Genomics, Gao Yang, is subject to judicial enforcement regarding the forced liquidation of a portion of his shares due to a breach of contract with Guoxin Securities [1][2]. Group 1: Shareholder and Legal Actions - Gao Yang, the controlling shareholder of Berry Genomics, holds 31,988,723 shares, accounting for 9.05% of the total share capital [1]. - The Chengdu Financial Court has ordered the forced liquidation of 3,535,214 shares held by Gao Yang due to a breach of a stock pledge repurchase agreement with Guoxin Securities [1][2]. - The enforcement action is based on a legally effective arbitration ruling from the Shenzhen International Arbitration Court [1]. Group 2: Financial Performance - Berry Genomics reported net profits attributable to shareholders of -117 million yuan in 2021, -249 million yuan in 2022, -427 million yuan in 2023, and -192 million yuan in 2024 [3]. - The company's operating revenue for 2024 is 1,078 million yuan, a decrease of 6.36% from 2023, which had revenue of 1,151 million yuan [4]. - The net profit attributable to shareholders for 2024 improved by 54.96% compared to 2023, indicating a reduction in losses [4].

Core Insights - Synthetic biology is at a pivotal growth point in China, attracting significant attention from global investors due to its unique innovation potential and broad application prospects [1] - The Chinese synthetic biology market comprises 116 listed companies, including technology platform providers, CXO companies offering biosynthesis solutions, and chemical and pharmaceutical companies seeking transformation [1] - The industry showcases a mix of established players with decades of experience and newly founded companies, highlighting the vast development potential and imagination space behind synthetic biology [1] Industry Overview - Enabling technology companies in synthetic biology are experiencing rapid growth, leveraging cutting-edge technologies such as gene editing, gene synthesis, gene sequencing, big data, and machine learning [1] - Current enabling technologies are still in their early stages, with high technical barriers, leading companies to pursue collaborations with universities, research institutions, and other enterprises to advance R&D [1] Leading Companies - BGI Genomics and Berry Genomics are recognized as leaders among enabling technology companies in China's synthetic biology sector [2] - BGI Genomics focuses on gene sequencing instruments, laboratory automation, and new business areas, enhancing its global influence in precision medicine and health [3] - Berry Genomics, a leader in gene sequencing, offers services in reproductive health, genetic disease detection, and tumor detection, supported by proprietary technologies like PCR-free methods [6] Platform Companies - Synthetic biology platform companies primarily provide services related to process improvement and enzyme engineering, with few achieving the functionality of cell factories [9] - Kingfisher Biotech is a prominent global gene supplier, evolving into a leading provider of research and production services with a strong reputation in life sciences [11] - Yikole Biotech specializes in synthetic biology technology, focusing on biomanufacturing and possessing a vast library of over 20,000 enzymes [13][16] Emerging Trends - The Chinese synthetic biology sector is witnessing a surge in investment opportunities driven by policy guidance and market demand, with companies increasing their focus on technological innovation and R&D [22] - Key application areas include biopharmaceutical raw materials, bio-based materials, and the development of cell and gene therapy drugs, supported by integrated R&D and production capabilities [16][20]

成都市贝瑞和康基因技术股份有限公司 关于持股5%以上股东所持部分股份被司法强制执行的提示性公告 证券代码：000710 证券简称：贝瑞基因 公告编号：2025-025 股东高扬先生保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、高扬先生持有成都市贝瑞和康基因技术股份有限公司（以下简称"公司"或 "贝瑞基因"）股份 31,988,723 股（占公司总股本比例为 9.05%），为公司控股股 东。现因高扬先生在国信证券股份有限公司（以下简称"国信证券"）开展的股票质 押回购业务发生违约，成渝金融法院裁定强制变现被执行人高扬先生持有的 3,535,214 股"贝瑞基因"股票。 2、公司目前生产经营情况正常，该事项未对公司的生产经营及财务状况产生重 大不利影响，未对公司治理结构产生重大不利影响。 公司于近日收到股东高扬先生通知，其于近日收到成渝金融法院作出的(2024) 渝 87 执 4703 号之三《执行裁定书》，裁定强制变现被执行人高扬先生持有的 3,535,214 股"贝瑞基因"股票。现将有关情况 ...

资金面上看，今日基因测序概念板块获主力资金净流入4.22亿元，其中，33股获主力资金净流入，10股 主力资金净流入超千万元，净流入资金居首的是贝瑞基因，今日主力资金净流入1.38亿元，净流入资金 居前的还有东方海洋、华大基因、美年健康等，主力资金分别净流入1.31亿元、1.26亿元、3326.88万 元。 截至5月13日收盘，基因测序概念上涨1.23%，位居概念板块涨幅第10，板块内，39股上涨，贝瑞基 因、东方海洋等涨停，华大基因、迪安诊断、华大智造等涨幅居前，分别上涨14.55%、8.27%、 6.89%。跌幅居前的有新芝生物、谱尼测试、茂莱光学等，分别下跌1.66%、1.62%、1.61%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 中韩自贸区 | 3.03 | 中船系 | -3.40 | | 航运概念 | 2.51 | 国产航母 | -2.37 | | 硅能源 | 2.30 | 军工信息化 | -2.16 | | 环氧丙烷 | 1.95 | 太赫兹 | -2.14 | | 阿尔茨海默概念 | 1 ...

Group 1 - The core viewpoint of the news highlights the recent performance and market position of Berry Genomics, noting a significant stock price increase and a low market-to-book ratio [1] - On May 13, Berry Genomics closed at 13.96 yuan, up 10.01%, with a market capitalization of 4.935 billion yuan and a price-to-book ratio of 2.96, marking a new low in 31 days [1] - The company experienced a net inflow of 137.79 million yuan in main funds on May 13, with a total inflow of 102.66 million yuan over the past five days, indicating a positive trend in capital flow [1] Group 2 - Berry Genomics specializes in gene testing services based on high-throughput sequencing technology, offering related equipment and reagent sales [1] - The company provides comprehensive solutions through "products + services" to hospitals and third-party medical laboratories, establishing a leadership position in the genetics field [1] - The latest financial report for Q1 2025 shows the company achieved revenue of 218 million yuan, a year-on-year decrease of 22.08%, with a net loss of approximately 6.46 million yuan, reflecting a year-on-year decline of 178.47% and a gross profit margin of 49.48% [1] Group 3 - In comparison to industry averages, Berry Genomics has a TTM PE ratio of -23.83 and a static PE ratio of -25.65, with a market capitalization of 4.935 billion yuan [2] - The industry average PE ratios are significantly higher, with the average TTM PE at 50.06 and the static PE at 45.92, indicating that Berry Genomics is underperforming relative to its peers [2] - The industry median market capitalization is 4.795 billion yuan, suggesting that Berry Genomics is positioned within a competitive landscape [2]

5月13日涨停分析 今日共48股涨停，连板股总数11只，19股封板未遂，封板率为71%（不含ST股、退市股）。焦点股方面，军工板块成飞集成、利君股份、天箭科技均晋级5 连板，化工股红墙股份16天10板，高外销占比的华纺股份反包涨停走出6天5板。 | 股票名称 | 板数 | 涨跌幅 | 涨停时间 | 上涨逻辑 | | --- | --- | --- | --- | --- | | 宝馨科技 | 6天4板 | 9.93% | 09:42 | 机器人+光 | | 002514 | | | | 伏 | | 百达精工 | 4天3板 | 9.98% | 14:10 | 压缩机+光 | | 603331 | | | | 伏 | | 鑫磊股份 | 4天2板 | 20.00% | 14:22 | 压缩机+光 | | 301317 | | | | 伏 | | 集泰股份 | 首板 | 9.97% | 09:36 | 光伏+有机 | | 002909 | | | | 硅 | | 欧晶科技 | 首板 | 9.98% | 09:41 | 光伏+半导 | | 001269 | | | | 体 | | 泉运通 | 首板 | 10.14% | ...

智通财经5月13日电，午后贝瑞基因涨停，华大基因涨超15%，迪安诊断、安必平、嘉和美康、美年健 康、润达医疗等涨幅靠前。消息面上，OpenAI宣布推出了一个专门面向医疗大模型的测试评估集 —— HealthBench 并开源，旨在更好地衡量 AI 系统在医疗健康领域能力，为进一步推动AI医疗技术的发展 和应用做出重要贡献。 AI医疗概念震荡走强 贝瑞基因涨停 ...

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential for future growth [20]. 4. Blood Products - The report highlights the strong pricing power of manufacturers in the blood products sector, driven by increased demand for immunoglobulin products [22]. 5. Vaccine Sector - The vaccine sector is facing challenges due to low birth rates, but there are opportunities in specific areas such as HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and overseas growth potential in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD sector is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drugs [37]. 9. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [42]. 10. Offline Pharmacies - The report indicates that leading pharmacy chains are stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [45]. 11. Raw Materials - The report emphasizes the importance of quality and cost management in the raw materials sector, suggesting a focus on companies with strong product capabilities [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in the medical device sector, particularly in surgical navigation and pathology screening [51]. 13. Instrument Equipment - The report notes that the scientific instrument sector is expected to recover as demand improves and more domestic support policies are introduced [56]. 14. Low-value Consumables - The report suggests that the low-value consumables sector may see investment opportunities as the industry cycle improves [59].